Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Low reporting rates of DDIs support the potential for NMV/r treatment to be safely managed with careful use of available drug interaction resources to aid in risk mitigation.
Authors
- Romina Quercia
- Lubna Merchant (ORCID: https://orcid.org/0000-0001-8891-287X)
- Florin Draica (ORCID: https://orcid.org/0000-0002-9489-5495)
- James M. Gerhart
- Iqra Arham (ORCID: https://orcid.org/0009-0002-7377-7913)
- Ayman Ayoub
- Reema Mehta
- Victoria Hendrick (ORCID: https://orcid.org/0000-0003-2364-7395)
- Erast Pohorylo
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1007/s40121-024-01050-w
- Citations
- 7
- Primary Topic
- Infectious Encephalopathies and Encephalitis
- Type
- article
- Field-Weighted Citation Impact
- 2.72